Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

6.140 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine Mindmed Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
31 32 Next >
Psychedelic Stock Gainers And Losers From March 22, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From March 21, 2023
Via Benzinga
EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
This is the third article of a three-part series, you can find the first and 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 20, 2023
Via Benzinga
Cannabis Category Performance Comparisons: An Update
Here is a summary of how each of the 5 categories in the cannabis sector has performed month-to-date, in descending order, and year-to-date. The picture isn't pretty. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 17, 2023
Via Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll... 
Via Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
MindMed Reports Full-Year 2022 Financial Results, Highlighting Anxiety & Autism Studies
Clinical-stage biopharma company Mind Medicine (MindMed), Inc. (NASDAQ: MNMD) shared its financial results for the full year ended Dec. 31, 2022. Numbers show solid stability: 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 9, 2023
Via Benzinga
MindMed Reports Full Year 2022 Financial Results and Business Highlights
From MindMed
Via Business Wire
Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 6, 2023
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
The 5 Cannabis Category Performances Have Ranged From +14.5% To -2.7% YTD
The 5 categories in the cannabis sector perform quite differently from each other. 
Via Talk Markets
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 2, 2023
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From February 28, 2023
Via Benzinga
MindMed to Participate in March Investor Conferences
From MindMed
Via Business Wire
Psychedelic Stock Gainers And Losers From February 27, 2023
Via Benzinga
"Multi-Bagger" Portfolio Outperforming "Rags-To-Riches" Portfolio By 2-To-1 Margin YTD
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 but perhaps some will bounce back with 
Via Talk Markets
Of The 6 Largest Psychedelic Drug Stocks, Only One Has Not Advanced YTD
The most critical financial information on the health of a company is whether, or not, it has a Net Positive Operating Cash Flow; its Altman -Z Score; its Piotroski F-Score; and the percentage... 
Via Talk Markets
Only 2 Of 5 Cannabis Categories Have Advanced YTD
The 5 categories in the cannabis sector perform quite differently from each other but YTD the common trend is mostly downward. 
Via Talk Markets
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.